Healthcare
Amarin Corporation plc(AMRN)
Live Price
Offline$16.03
+1.65% today
Window Change
+10.63%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $290.00M
- Revenue Growth
- -6.5%
- EPS Growth
- +55.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Amarin Corporation plc (AMRN) is a Healthcare stock with a market cap of $290.00M and listed on NASDAQ. The stock last traded around $16.03 and up 10.6% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of -6.5%, EPS growth of +55.0%, a dividend yield of 0.0%. What stands out right now is revenue -6.5%, EPS +55.0%, free cash flow +121.7% with operating margin -17.4% and ROIC -7.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AMRN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-6.5% vs +7.6% peer median
Operating Margin
Below sector median
-17.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -6.5% and EPS is at +55.0%, with operating margin around -17.4%.
Benchmark Edge
AMRN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AMRN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AMRN Max Drawdown
-5.02%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AMRN and SPY.
Company Overview
Amarin Corporation plc
NASDAQ Global Market
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Leadership
- Aaron D. Berg
- IPO Date
- Apr 1, 1993
- Employees
- 275
- Street Address
- Grand Canal Docklands
- Mailing
- Dublin, 2
- Region
- Dublin, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 669 9020
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.4
- Price/Book
- 0.7
Growth
- Revenue
- -6.5%
- EPS
- +55.0%
- Free Cash Flow
- +121.7%
Profitability
- Gross Margin
- 52.5%
- Operating Margin
- -17.4%
- Net Margin
- -15.6%
- ROE
- -7.3%
- ROIC
- -7.8%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.48
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.